ESTROGENS AND ATHEROSCLEROTIC VASCULAR-DISEASE - LIPID FACTORS

被引:36
作者
NEWNHAM, HH
机构
来源
BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM | 1993年 / 7卷 / 01期
关键词
D O I
10.1016/S0950-351X(05)80271-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease remains the major cause of death for postmenopausal women in Western societies. The majority of epidemiological studies indicate that postmenopausal oestrogen replacement therapy is associated with a 50% reduction in the risk of cardiovascular disease, with much of the reduction being mediated by changes in the plasma concentration of cholesterol within high and low density lipoproteins. In addition to favourably influencing the plasma concentration of lipoproteins, oestrogens also influence the complex metabolism of lipoproteins in the arterial wall, helping to impede the formation of the atherosclerotic plaque. Whilst oestrogens alter endothelial function, vascular reactivity and fibrinolysis, these changes are also seen with reduction of LDL cholesterol and may partly reflect the altered concentration of plasma lipoproteins induced by oestrogens. Oral oestrogens have substantially greater favourable effect on LDL and HDL cholesterol than their transdermal counterparts but also result in greater hypertriglyceridaemia. Most progestogens antagonize the beneficial effects of oestrogens on lipoproteins in a dose-dependent manner; however, cyclical use of low doses of progestogens with an oral oestrogen generally retains a net beneficial effect. Lipoprotein levels fluctuate during cyclical therapy, the most adverse changes being noted at the end of the progestogen phase. Lipoprotein concentrations are constant during continuous combined regimens which have the potential for more prolonged exposure to an adverse progestational effect. Despite adverse effects on the lipoprotein profile, animal studies suggest that progestogens do not substantially reverse the beneficial effects of oestrogens on the development of atherosclerosis. Finally, oestrogen therapy may be useful in the managmeent of postmenopausal women with hyperlipidaemia, and also in the secondary prevention of clinical sequelae in women with established atherosclerosis. © 1993 Baillière Tindall.
引用
收藏
页码:61 / 93
页数:33
相关论文
共 144 条
[11]  
BASDEVANT A, 1982, J GYNECOL OBST BIO R, V11, P277
[12]  
BASDEVANT A, 1991, FERTIL STERIL, V55, P1112
[13]  
BASS K, 1991, CIRCULATION S2, V84
[14]   REPRODUCTIVE HISTORY IN WOMEN WITH CORONARY HEART-DISEASE - A CASE-CONTROL STUDY [J].
BEARD, CM ;
FUSTER, V ;
ANNEGERS, JF .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1984, 120 (01) :108-114
[15]  
BERR F, 1986, J LIPID RES, V27, P645
[16]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[17]   NORMAL BUT NOT HYPERTRIGLYCERIDEMIC VERY LOW-DENSITY LIPOPROTEIN INDUCES RAPID RELEASE OF TISSUE PLASMINOGEN-ACTIVATOR FROM CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS [J].
BOOYSE, FM ;
BRUCE, R ;
GIANTURCO, SH ;
BRADLEY, WA .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1988, 14 (02) :175-179
[18]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[19]   EFFECT OF COMBINED IMPLANTS OF ESTRADIOL AND TESTOSTERONE ON LIBIDO IN POSTMENOPAUSAL WOMEN [J].
BURGER, H ;
HAILES, J ;
NELSON, J ;
MENELAUS, M .
BRITISH MEDICAL JOURNAL, 1987, 294 (6577) :936-937
[20]   THE MANAGEMENT OF PERSISTENT MENOPAUSAL SYMPTOMS WITH ESTRADIOL TESTOSTERONE IMPLANTS - CLINICAL, LIPID AND HORMONAL RESULTS [J].
BURGER, HG ;
HAILES, J ;
MENELAUS, M ;
NELSON, J ;
HUDSON, B ;
BALAZS, N .
MATURITAS, 1984, 6 (04) :351-358